bluebird bio Inc(NASDAQ:BLUE) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 3, 2016. Company reported revenue of $1.55M. Analysts estimated a revenue of $2.20M. Earnings per share were $-1.59.
In a different note, Cantor Fitzgerald said it Initiates Coverage on bluebird bio Inc, according to a research note issued on Jun 2, 2016. The shares have been rated ‘Hold’ by the firm.
bluebird bio Inc (BLUE) made into the market gainers list on Fridays trading session with the shares advancing 2.38% or 1.32 points. Due to strong positive momentum, the stock ended at $56.8, which is also near the day’s high of $57.06. The stock began the session at $55.49 and the volume stood at 5,31,279 shares. The 52-week high of the shares is $143.08 and the 52 week low is $35.37. The company has a current market capitalization of $2,111 M and it has 3,71,69,965 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Jul 29, 2016, Eric Sullivan (Principal Accounting Officer) sold 2,912 shares at $55.01 per share price.Also, On Jul 19, 2016, David Davidson (Chief Medical Officer) sold 1,000 shares at $45.08 per share price.On Jun 16, 2016, Philip D Gregory (Chief Scientific Officer) sold 2,931 shares at $39.52 per share price, according to the Form-4 filing with the securities and exchange commission.
bluebird bio Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. The Company’s products include Lenti-D LentiGlobin and CAR T Cells. The Company is developing Lenti-D to treat patients with CCALD (Childhood cerebral adrenoleukodystrophy) the severe form of ALD (Adrenoleukodystrophy). The Company is conducting a Phase II/III clinical study of Lenti-D in the United States. The Company is developing LentiGlobin to treat patients with b-thalassemia and severe SCD (sickle cell disease). The Company is conducting a Phase I/II clinical study of LentiGlobin. It also initiated a second Phase I/II clinical study in the United States Australia and Thailand for LentiGlobin. The Company is developing CAR T cell technology to deliver T cells engineered to kill the cancer.